MedTrace Logo

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

NCT02655549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-07-11

No results posted yet for this study

Summary

The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.

Conditions

  • Anthrax

Interventions

BIOLOGICAL

Px563L, RPA563, or placebo

Two intramuscular injections

Sponsors & Collaborators

Principal Investigators

  • Barbara K Lomeli, M.D. · Quintiles Phase One Services, LLC

  • Hubert C Chen, M.D. · Pfenex, Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655549 on ClinicalTrials.gov